Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Satoh T, et al. Among authors: mukaiyama a. J Clin Oncol. 2014 Jul 1;32(19):2039-49. doi: 10.1200/JCO.2013.53.6136. Epub 2014 May 27. J Clin Oncol. 2014. PMID: 24868024 Clinical Trial.
Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
Nakagawa K, Minami H, Kanezaki M, Mukaiyama A, Minamide Y, Uejima H, Kurata T, Nogami T, Kawada K, Mukai H, Sasaki Y, Fukuoka M. Nakagawa K, et al. Among authors: mukaiyama a. Jpn J Clin Oncol. 2009 Feb;39(2):116-23. doi: 10.1093/jjco/hyn135. Epub 2008 Dec 3. Jpn J Clin Oncol. 2009. PMID: 19052038 Clinical Trial.
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A, Nakagawa K, Nagashima F, Shimizu T, Naruge D, Nishina S, Kitamura H, Kurata T, Takasu A, Fujisaka Y, Okamoto W, Nishimura Y, Mukaiyama A, Matsushita H, Furuse J. Kasuga A, et al. Among authors: mukaiyama a. Invest New Drugs. 2015 Oct;33(5):1058-67. doi: 10.1007/s10637-015-0270-2. Epub 2015 Aug 12. Invest New Drugs. 2015. PMID: 26259955 Clinical Trial.
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, Yoshikawa S, Fujiwara Y, Kondo S, Mukaiyama A, Zhang F, Kiyohara Y. Yamazaki N, et al. Among authors: mukaiyama a. J Dermatol. 2018 Apr;45(4):397-407. doi: 10.1111/1346-8138.14210. Epub 2018 Feb 5. J Dermatol. 2018. PMID: 29399853 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.
Fujiwara Y, Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Mukaiyama A, Zhang F, Tamura T. Fujiwara Y, et al. Among authors: mukaiyama a. Invest New Drugs. 2018 Apr;36(2):259-268. doi: 10.1007/s10637-017-0502-8. Epub 2017 Sep 7. Invest New Drugs. 2018. PMID: 28879519 Clinical Trial.
Regulation mechanisms of the dual ATPase in KaiC.
Furuike Y, Mukaiyama A, Koda SI, Simon D, Ouyang D, Ito-Miwa K, Saito S, Yamashita E, Nishiwaki-Ohkawa T, Terauchi K, Kondo T, Akiyama S. Furuike Y, et al. Among authors: mukaiyama a. Proc Natl Acad Sci U S A. 2022 May 10;119(19):e2119627119. doi: 10.1073/pnas.2119627119. Epub 2022 May 4. Proc Natl Acad Sci U S A. 2022. PMID: 35507871 Free PMC article.
38 results